Published in Vaccine Weekly, March 1st, 2006
"The ZD1839 (Iressa, gefitinib) treatment in phase I trials for patients with advanced NSCLC was associated with disease stabilization and tumor regression. The aim of this study was to analyze the efficacy of gefitinib monotherapy as a second- or third-line treatment for locally-advanced and advanced NSCLC," investigators in Hungary reported.
"Data for 50 patients were analyzed. Patients were treated at 5 centers in Hungary as part of the gefitinib Expanded Access Program (EAP). The response rate was 10% (all partial responses), with disease stabilization in 46% of patients....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.